Stockreport

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Sensei Biotherapeutics, Inc.  (SNSE) 
PDF - Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination [Read more]